Biosidus is a global company, headquartered in Argentina, that supplies injectable biological medicines to over 60 countries – changing the lives of millions of patients that need treatments in emerging markets.

With over 30 years of innovation in biological drugs that treat challenging and rare medical conditions, we have developed a portfolio of nine biosimilars in various formulations and delivery formats, and we also have distribution licenses with large pharma companies for a further range of biologics that we make accessible and affordable to patients worldwide.

Improving Quality of Life with Biosimilars

Biosimilars are complex injectable drugs produced from living organisms that are similar in structure and function to a reference biological drug whose patent has expired. Biosimilars are subject to the same regulatory approvals and pharmacovigilance to ensure quality and safety for patients. They provide effective treatment options for many chronic, rare, and sometimes life-threatening medical conditions including autoimmune diseases and cancer.

Biosimilars benefit from more economical development and production costs than the reference biologic, which means they can be provided to patients and public health systems at lower price points, which potentially dramatically increases access for more diverse populations globally who may previously have had no accessible treatments. Increasing approvals of biosimilars in mature markets will also bring competition, lower cost care, and more treatment options.

Product Innovation

Biosidus has had an R&D team comprising a small, talented group of scientists since the company launched in its current form in the 1990s. This group has developed nine biosimilars that are now commercially available and changing the lives of patients in more than 60 countries.

We are currently in Phase III trials with our 10th biosimilar – Agalsidase beta – which we aim to launch in Argentina in 2025 and subsequently in other key emerging markets. This innovative treatment for Fabry disease was developed in-house by our R&D team, starting with the cell line, followed by development of the manufacturing process, quality control, and the galenic formulation.